We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.
An-Chi Tien, PhDPharmacodynamics Core Leader
Dr. An-Chi Tien received his Ph.D. from Baylor College of Medicine in Houston, Texas, before completing a postdoctoral fellowship in…